Newswire (Published: Tuesday, January 31, 2017, Received: Thursday, January 26, 2017, 3:36:19 PM CST)
Word Count: 432
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Melbourne, Australia, by NewsRx journalists, research stated, "Localised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer."
The news reporters obtained a quote from the research from the University of Melbourne, "Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms. We aimed to?provide a comprehensive review of the current prostate cancer biomarkers available and in development. MEDLINE and EMBASE databases searches were conducted to identify articles pertaining to the use of novel biomarkers for prostate cancer. A growing number of novel biomarkers are currently under investigation. Such markers include urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic markers. While limited clinical data is present for analysis, early results appear promising. Specifically, a combination of serum and urinary biomarkers (Serum PSA + Urinary PCA3 + Urinary TMPRSS2-ERG fusion) appears to provide superior sensitivity and specificity profiles compared to traditional diagnostic approaches (AUC 0.88). The accurate diagnosis and risk stratification of prostate cancer is critical to ensure appropriate intervention. The development of non-invasive biomarkers can add to the information provided by current screening practices and allows for individualised risk stratification of patients. The use of these biomarkers appears to increase the sensitivity and specificity of diagnosis of prostate cancer."
According to the news reporters, the research concluded: "Further studies are necessary to define the appropriate use and time points of each biomarker and their effect on the management algorithm of prostate cancer."
For more information on this research see: Prostate cancer biomarkers: Are we hitting the mark? Prostate International, 2016;4(4):130-135 (see also Oncology - Prostate Cancer).
Our news correspondents report that additional information may be obtained by contacting S. McGrath, Dept. of Surgery, University of Melbourne, Austin Health, Melbourne, Australia. Additional authors for this research include D. Christidis, M. Perera, S.K. Hong, T. Manning, I. Vela and N. Lawrentschuk.
Keywords for this news article include: Genetics, Oncology, Melbourne, Cancer Risk, Article Review, Prostatic Neoplasms, Risk and Prevention, Australia and New Zealand, Diagnostics and Screening, Metastatic Prostate Cancer.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
University of Melbourne
Australia and New Zealand
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues